rbsmorgans /up to test-osterone

Rbsmorgans reported today that eli lilly has launched an extensive direct to consumer tv advertising campaign to support axiron and raise awareness about testosterone deficiency so we can expect the current uptake rate(1% per month )will be sustained for at least the next year.They are confident that their target of 40% market share by fy14 is achievable.Axiron target market is worth us$1.5 billion and growing at 15 to 20% per annum.(Eli lilly must be very confident of the potential of axiron to be spending big bucks on tv ads).They mentioned that the key milestone for acr is securing the patent on axiron in usa which they expect will transpire in 1qcy12 and they believe this could be a catalyst for corporate activity.(Target price after patent at least $4.59).